CONMED Corp (CNMD): Scopia Capital Isn’t Done Buying Shares

Published on March 10, 2016 at 12:22 am by Meena Krishnamsetty in Hedge Funds,News

Page 1 of 22

Two weeks after Matt Sirovich and Jeremy Mindich‘s Scopia Capital first revealed a large position in CONMED Corporation (NASDAQ:CNMD), the investment firm has filed another 13D on the company which shows that it has continued to buy shares of it since. The firm now owns 2.09 million shares of the medical supplies company, up from 1.69 million shares as of the February 23 filing which revealed the new holding. You can see the latest ownership information in the table below.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
SCOPIA PX	542,427	2,093,148	542,427	2,093,148	542,427	2.0%
SCOPIA PARTNERS	15,099	2,093,148	15,099	2,093,148	15,099	Less than 1%
SCOPIA HEALTH CARE	41,342		41,342		41,342	Less than 1%
SCOPIA WINDMILL FUND	382,036		382,036		382,036	1.4%
SCOPIA INTERNATIONAL MASTER FUND	95,331		95,331		95,331	Less than 1%
SCOPIA PX INTERNATIONAL MASTER FUND	688,144		688,144		688,144	2.5%
SCOPIA HEALTH CARE INTERNATIONAL MASTER FUND	300,900		300,900		300,900	1.1%
SCOPIA CAPITAL GP	2,065,279		2,065,279		2,065,279	7.5%
SCOPIA CAPITAL MANAGEMENT	2,093,148		2,093,148		2,093,148	7.6%
SCOPIA MANAGEMENT, INC	2,093,148		2,093,148		2,093,148	7.6%
MATTHEW SIROVICH					2,093,148	7.6%
JEREMY MINDICH					2,093,148	7.6%

Matt Sirovich And Jeremy Mindich

Scopia Capital

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 1 of 22 SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

§ 240.13d-2(a)

(Amendment No. 2)1

CONMED Corporation

(Name of Issuer)

Common Stock, $0.01 par value

(Title of Class of Securities)

207410101

(CUSIP Number)

SAMANTHA NASELLO

SCOPIA CAPITAL MANAGEMENT LP

152 West 57th Street, 33rd Floor

New York, New York 10019

(212) 370-0303

STEVE WOLOSKY

OLSHAN FROME WOLOSKY LLP

Park Avenue Tower

65 East 55th Street

New York, New York 10022

(212) 451-2300

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

March 7, 2016

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

_______________

1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Conmed Corp (NASDAQ:CNMD)Follow Conmed Corp (NASDAQ:CNMD)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 1 of 22

Next >>

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.

We may use your email to send marketing emails about our services. Click here to read our privacy policy.